HUE039219T2 - Pharmaceutical composition for treatment and/or prophylaxis of cancer - Google Patents
Pharmaceutical composition for treatment and/or prophylaxis of cancerInfo
- Publication number
- HUE039219T2 HUE039219T2 HUE12820091A HUE12820091A HUE039219T2 HU E039219 T2 HUE039219 T2 HU E039219T2 HU E12820091 A HUE12820091 A HU E12820091A HU E12820091 A HUE12820091 A HU E12820091A HU E039219 T2 HUE039219 T2 HU E039219T2
- Authority
- HU
- Hungary
- Prior art keywords
- prophylaxis
- cancer
- treatment
- pharmaceutical composition
- pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011171377 | 2011-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE039219T2 true HUE039219T2 (en) | 2018-12-28 |
Family
ID=47629405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12820091A HUE039219T2 (en) | 2011-08-04 | 2012-08-03 | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9175074B2 (en) |
| EP (1) | EP2740794B1 (en) |
| JP (1) | JP6065590B2 (en) |
| KR (1) | KR101980557B1 (en) |
| CN (1) | CN103717739B (en) |
| AU (1) | AU2012290954B2 (en) |
| BR (1) | BR112014002613B1 (en) |
| CA (1) | CA2844040C (en) |
| DK (1) | DK2740794T3 (en) |
| ES (1) | ES2672695T3 (en) |
| HU (1) | HUE039219T2 (en) |
| MX (1) | MX348578B (en) |
| PL (1) | PL2740794T3 (en) |
| PT (1) | PT2740794T (en) |
| RU (1) | RU2610428C2 (en) |
| TR (1) | TR201808595T4 (en) |
| WO (1) | WO2013018891A1 (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2733492T3 (en) | 2008-08-05 | 2016-04-25 | Toray Industries | Method for detection of cancer |
| CN102170907A (en) | 2008-08-05 | 2011-08-31 | 东丽株式会社 | Pharmaceutical composition for treatment and prevention of cancer |
| MX340015B (en) * | 2010-02-04 | 2016-06-22 | Toray Industries | Pharmaceutical composition for treatment and/or prevention of cancer. |
| PT2740489T (en) * | 2011-08-04 | 2017-01-10 | Toray Industries | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
| CA2844033C (en) | 2011-08-04 | 2021-07-27 | Toray Industries, Inc. | Method for detecting pancreatic cancer |
| DK2818483T3 (en) | 2012-02-21 | 2017-10-23 | Toray Industries | Medical composition for the treatment and / or prevention of cancer |
| PT2832365T (en) | 2012-03-30 | 2018-01-24 | Toray Industries | Pharmaceutical composition for treatment and/or prevention of liver cancer |
| US9428581B2 (en) | 2012-03-30 | 2016-08-30 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of gallbladder cancer |
| RU2646466C2 (en) | 2012-07-19 | 2018-03-05 | Торэй Индастриз, Инк. | Method for cancer detection |
| WO2014014086A1 (en) * | 2012-07-19 | 2014-01-23 | 東レ株式会社 | Cancer detection method |
| JP6447130B2 (en) | 2013-08-09 | 2019-01-09 | 東レ株式会社 | Pharmaceutical composition for treatment and / or prevention of cancer |
| MY176206A (en) * | 2013-12-26 | 2020-07-24 | Vitro Flat Glass Llc | Organic light emitting diode with light extracting electrode |
| KR20230149857A (en) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Antibody adjuvant conjugates |
| EP3533466A4 (en) | 2016-10-28 | 2020-06-10 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| EP3777888A4 (en) | 2018-03-30 | 2021-12-01 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| CA3130794A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| JP7281951B2 (en) * | 2019-04-22 | 2023-05-26 | シャープ株式会社 | ELECTRONIC DEVICE, CONTROL DEVICE, CONTROL PROGRAM AND CONTROL METHOD |
| MX2021015221A (en) | 2019-06-13 | 2022-03-17 | Bolt Biotherapeutics Inc | Aminobenzazepine compounds, immunoconjugates, and uses thereof. |
| EP4038053A1 (en) | 2019-09-30 | 2022-08-10 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
| AU2020369652A1 (en) | 2019-10-25 | 2022-05-12 | Bolt Biotherapeutics, Inc. | Thienoazepine immunoconjugates, and uses thereof |
| US20230139178A1 (en) | 2020-03-12 | 2023-05-04 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CA3175279A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2021182572A1 (en) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | Medicament for treatment and/or prevention of cancer |
| BR112022018157A2 (en) | 2020-03-12 | 2022-10-25 | Toray Industries | DRUG FOR THE TREATMENT AND/OR PREVENTION OF CANCER, AGENTS THAT INCREASE THE EFFICACY OF A DRUG AND METHOD FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
| EP4119158A4 (en) | 2020-03-12 | 2024-05-08 | Toray Industries | Medicament for treatment and/or prevention of cancer |
| JP2023524271A (en) | 2020-05-08 | 2023-06-09 | ボルト バイオセラピューティクス、インコーポレーテッド | Elastase-substrate peptide linker immunoconjugates and uses thereof |
| US20230263903A1 (en) | 2020-08-13 | 2023-08-24 | Bolt Biotherapeutics, Inc. | Pyrazoloazepine immunoconjugates, and uses thereof |
| AU2022298240A1 (en) | 2021-06-23 | 2024-01-18 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| KR20240024074A (en) | 2021-06-23 | 2024-02-23 | 도레이 카부시키가이샤 | Medicines for the treatment and/or prevention of cancer |
| WO2023008462A1 (en) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | Medicament for treatment and/or prevention of cancer |
| AU2022319362A1 (en) | 2021-07-27 | 2024-02-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CN117651566A (en) | 2021-07-27 | 2024-03-05 | 东丽株式会社 | Medicine for treating and/or preventing cancer |
| CA3230737A1 (en) | 2021-09-03 | 2023-03-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| WO2023076599A1 (en) | 2021-10-29 | 2023-05-04 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1996002576A1 (en) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| FR2761994B1 (en) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | PREPARATION OF MEMBRANE RECEPTORS FROM EXTRACELLULAR BACULOVIRUSES |
| CA2325346A1 (en) | 1998-04-03 | 1999-10-14 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| RU2234942C2 (en) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Tumor polypeptide isolated from prostate and polynucleotide encoding thereof |
| CZ2001149A3 (en) | 1998-07-14 | 2002-02-13 | Corixa Corporation | Preparations and methods for therapy and diagnostic of prostate carcinoma |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
| EP1187915A2 (en) | 1999-04-02 | 2002-03-20 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| CA2388822A1 (en) | 1999-10-29 | 2001-05-10 | Human Genome Sciences, Inc. | 27 human secreted proteins |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| PL366626A1 (en) | 2000-03-29 | 2005-02-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| AU3942202A (en) | 2000-11-30 | 2002-06-11 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (en) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Method for treating the cases of malignant tumors containing b-cells with a combination of applications related to antibodies reducing b-cells number and with immunomodulating antibodies |
| AU2002311787A1 (en) | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
| WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| AU2002311909A1 (en) | 2001-05-11 | 2002-11-25 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| EP1632571B1 (en) | 2001-05-11 | 2012-11-28 | Kyowa Hakko Kirin Co., Ltd. | Human artificial chromosome containing human antibody Lambda light chain and non-human animal containing the human artificial chromosome capable of genetic transmission |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20040258678A1 (en) | 2002-02-22 | 2004-12-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| AU2003302386B2 (en) | 2002-11-26 | 2010-04-01 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
| US20050202451A1 (en) | 2003-04-29 | 2005-09-15 | Burczynski Michael E. | Methods and apparatuses for diagnosing AML and MDS |
| CA2528669A1 (en) | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2005007830A2 (en) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| EP2361929A1 (en) | 2004-01-26 | 2011-08-31 | Debiovision Inc. | Neoplasm-specific polypeptides and their use |
| ES2387809T3 (en) | 2004-03-19 | 2012-10-02 | Imclone Llc | Antibody to human epidermal growth factor receptor |
| SG151292A1 (en) | 2004-03-30 | 2009-04-30 | Glaxo Group Ltd | Immunoglobulins |
| WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| PL1846030T3 (en) | 2005-01-21 | 2019-05-31 | Genentech Inc | Fixed dosing of her antibodies |
| US7858324B2 (en) | 2005-02-18 | 2010-12-28 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
| CA2602088C (en) | 2005-03-11 | 2021-07-27 | Ciphergen Biosystems, Inc. | Biomarkers for ovarian cancer and endometrial cancer |
| JP2006316040A (en) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(r) adjuvant treatment |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| EP1991701A4 (en) | 2006-02-14 | 2010-03-17 | Dana Farber Cancer Inst Inc | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| WO2008073162A2 (en) | 2006-08-17 | 2008-06-19 | Cell Signaling Technology, Inc. | Lysine acetylation sites |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| WO2008031041A2 (en) | 2006-09-07 | 2008-03-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| US20100008928A1 (en) * | 2006-10-06 | 2010-01-14 | Takeda Phamarmaceutical Company Limited | Agent for preventing/treating cancer |
| WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
| JP5663834B2 (en) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | Method for producing recombinant antibody |
| KR102009241B1 (en) * | 2008-08-05 | 2019-08-09 | 도레이 카부시키가이샤 | Immunity inducer |
| CN102170907A (en) | 2008-08-05 | 2011-08-31 | 东丽株式会社 | Pharmaceutical composition for treatment and prevention of cancer |
| DK2733492T3 (en) | 2008-08-05 | 2016-04-25 | Toray Industries | Method for detection of cancer |
| PT2467401T (en) | 2009-08-19 | 2017-04-26 | Merck Patent Gmbh | Antibodies for the detection of integrin complexes in ffpe material |
| MX2012003404A (en) | 2009-09-22 | 2012-09-12 | Volker Sandig | Process for producing molecules containing specialized glycan structures. |
| PT2532367T (en) | 2010-02-04 | 2018-11-09 | Toray Industries | Pharmaceutical agent for treatment and/or prevention of cancer |
| CA2788547C (en) | 2010-02-04 | 2018-06-05 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| CA2788716C (en) | 2010-02-04 | 2019-06-18 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| BR112012018948B1 (en) | 2010-02-04 | 2021-12-14 | Toray Industries, Inc | PHARMACEUTICAL COMPOSITIONS, ANTIBODIES, PHARMACEUTICAL COMBINATION, USES OF A PHARMACEUTICAL COMPOSITION, USE OF AN ANTIBODY AND USE OF A PHARMACEUTICAL COMBINATION |
| US9115200B2 (en) | 2010-02-04 | 2015-08-25 | Toray Industries, Inc. | Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1 |
| MX340015B (en) | 2010-02-04 | 2016-06-22 | Toray Industries | Pharmaceutical composition for treatment and/or prevention of cancer. |
| JP2011171377A (en) | 2010-02-16 | 2011-09-01 | Covalent Materials Corp | Method of manufacturing silicon wafer |
| CA2844033C (en) | 2011-08-04 | 2021-07-27 | Toray Industries, Inc. | Method for detecting pancreatic cancer |
| PT2740489T (en) | 2011-08-04 | 2017-01-10 | Toray Industries | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
| PL2740796T3 (en) | 2011-08-04 | 2017-10-31 | Toray Industries | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| US9428581B2 (en) * | 2012-03-30 | 2016-08-30 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of gallbladder cancer |
| PT2832365T (en) * | 2012-03-30 | 2018-01-24 | Toray Industries | Pharmaceutical composition for treatment and/or prevention of liver cancer |
-
2012
- 2012-08-03 JP JP2012543816A patent/JP6065590B2/en active Active
- 2012-08-03 PL PL12820091T patent/PL2740794T3/en unknown
- 2012-08-03 RU RU2014108043A patent/RU2610428C2/en active
- 2012-08-03 CA CA2844040A patent/CA2844040C/en active Active
- 2012-08-03 EP EP12820091.2A patent/EP2740794B1/en active Active
- 2012-08-03 TR TR2018/08595T patent/TR201808595T4/en unknown
- 2012-08-03 MX MX2014001371A patent/MX348578B/en active IP Right Grant
- 2012-08-03 KR KR1020147005859A patent/KR101980557B1/en active IP Right Grant
- 2012-08-03 ES ES12820091.2T patent/ES2672695T3/en active Active
- 2012-08-03 HU HUE12820091A patent/HUE039219T2/en unknown
- 2012-08-03 BR BR112014002613-0A patent/BR112014002613B1/en active IP Right Grant
- 2012-08-03 US US14/236,859 patent/US9175074B2/en active Active
- 2012-08-03 WO PCT/JP2012/069853 patent/WO2013018891A1/en active Application Filing
- 2012-08-03 CN CN201280038467.4A patent/CN103717739B/en active Active
- 2012-08-03 AU AU2012290954A patent/AU2012290954B2/en active Active
- 2012-08-03 DK DK12820091.2T patent/DK2740794T3/en active
- 2012-08-03 PT PT128200912T patent/PT2740794T/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014002613B1 (en) | 2022-08-23 |
| EP2740794B1 (en) | 2018-04-04 |
| MX2014001371A (en) | 2014-03-21 |
| RU2610428C2 (en) | 2017-02-10 |
| CA2844040C (en) | 2019-05-07 |
| AU2012290954A1 (en) | 2014-03-20 |
| EP2740794A1 (en) | 2014-06-11 |
| KR101980557B1 (en) | 2019-05-21 |
| RU2014108043A (en) | 2015-09-10 |
| AU2012290954B2 (en) | 2017-08-31 |
| TR201808595T4 (en) | 2018-07-23 |
| US20140154261A1 (en) | 2014-06-05 |
| MX348578B (en) | 2017-06-20 |
| BR112014002613A2 (en) | 2018-06-05 |
| CN103717739A (en) | 2014-04-09 |
| CN103717739B (en) | 2015-07-29 |
| US9175074B2 (en) | 2015-11-03 |
| PL2740794T3 (en) | 2018-09-28 |
| KR20140054180A (en) | 2014-05-08 |
| EP2740794A4 (en) | 2015-04-22 |
| WO2013018891A1 (en) | 2013-02-07 |
| JP6065590B2 (en) | 2017-01-25 |
| PT2740794T (en) | 2018-06-14 |
| DK2740794T3 (en) | 2018-06-14 |
| ES2672695T3 (en) | 2018-06-15 |
| JPWO2013018891A1 (en) | 2015-03-05 |
| CA2844040A1 (en) | 2013-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2740796A4 (en) | Pharmaceutical composition for treatment and/or prophylaxis of cancer | |
| HUE039219T2 (en) | Pharmaceutical composition for treatment and/or prophylaxis of cancer | |
| EP2818482A4 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
| EP2818481A4 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
| EP2824114A4 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
| EP2740489A4 (en) | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer | |
| EP2740793A4 (en) | Drug composition for cancer treatment and/or prevention | |
| PT2832366T (en) | Pharmaceutical composition for treatment and/or prevention of gallbladder cancer | |
| PL2532365T3 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
| PL2532743T3 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
| PL2832365T3 (en) | Pharmaceutical composition for treatment and/or prevention of liver cancer | |
| PL2740795T3 (en) | Cancer treatment and/or prevention drug composition | |
| PL3031826T3 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
| EP2740798A4 (en) | Cancer treatment and/or prevention drug composition | |
| EP2688594A4 (en) | Methods and compositions for the treatment of cancer | |
| EP2709614A4 (en) | Pharmaceutical compositions and methods for treating cancer | |
| EP2962693A4 (en) | Pharmaceutical composition for prevention and/or treatment of cancer | |
| SG11201400976WA (en) | Methods and pharmaceutical compositions for treating cancer | |
| EP2687231A4 (en) | Composition for treatment and diagnosis of pancreatic cancer | |
| EP2928456A4 (en) | Methods and compositions for treatment of cancer | |
| IL221238A0 (en) | Pharmaceutical compositions and methods for the treatment and prevention of cancer | |
| ZA201107399B (en) | Method and compositions for treatment of cancer | |
| HUP1100245A2 (en) | Pharmaceutical composition for the treatment of wounds |